|
||
Stugeron-Janssen Overdose |
||
Symptoms: Overdose may be fatal especially in infants and children in whom the main symptoms are central nervous system (CNS) stimulation and antimuscarinic effects including ataxia, excitement, hallucinations, muscle tremor, convulsions, dilated pupils, dry mouth, flushed face and hyperpyrexia. Deepening coma, cardiorespiratory collapse and death may occur within 18 hrs. In adults, the usual symptoms are CNS depression with drowsiness, coma and convulsions. Hypertension may also occur.
Treatment: Treatment is symptomatic and supportive.
As with other antihistamines, this medicine may cause epigastric discomfort; taking it after meals may diminish the gastric irritation.
In patients with Parkinson’s Disease, this medicine should only be given if the advantages outweigh the possible risk of aggravating this disease.
Because of its antihistamine effect, this medicine may prevent an otherwise positive reaction to dermal reactivity indicators if used within 4 days prior to testing.
Use of Stugeron-Janssen should be avoided in porphyria.
There have been no specific studies in hepatic or renal dysfunction. this medicine should be used with care in patients with hepatic or renal insufficiency.
Patients with rare hereditary problems of fructose or galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency, should not take this medicine because it contains lactose andh
As with other antihistamines, Stugeron-Janssen may cause epigastric distress; taking it after meals may diminish gastric irritation.
In patients with Parkinson's disease, Stugeron-Janssen should only be given if the advantages outweigh the possible risk of aggravating this disease.
Stugeron-Janssen may cause somnolence, especially at the start of treatment.
Caution should be taken when alcohol or CNS depressants are used concomitantly.
Effects on the Ability to Drive or Operate Machinery: Since somnolence may occur, caution should be taken during driving or operating dangerous machinery.
Use in pregnancy & lactation: Although in animal studies Stugeron-Janssen has shown no teratogenic effects, as with all drugs, it should be used during pregnancy only if the therapeutic benefits justify the potential risks for the foetus.
There are insufficient data on the excretion of Stugeron-Janssen in human breast milk, therefore therapy should be discouraged in nursing women.
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|